Alström Syndrome
New Alström syndrome research, summarized each month in plain language.
2026 so far: In January 2026 to September 2026, small real-world reports followed dulaglutide and ertugliflozin with improved blood sugar measures, while lab studies explored obesity biology and case reports highlighted how variable heart findings can be. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Diabetes and weight medicines. Human treatment evidence stayed limited to small case reports.
- Heart and hospital care. Case reports broadened the range of real-world management scenarios.
- How diagnosis was made. Reports highlighted both the value and limits of genetic confirmation.
- Obesity biology targets. Lab work increasingly pinpointed early metabolic signals and mechanisms.
- Models and biomarkers. More models and exploratory markers appeared, clinical meaning unclear.
New
September 2026
- Deep belly fat cells. In mouse-derived fat precursor cells, ALMS1 loss reduced deep-belly fat cell formation.
- Primary cilia changes. Primary cilia signaling changes may be linked to this effect.
- Oral bacteria signals. Mouth bacteria and fluid chemistry differed, but clinical value is unclear.
August 2026
- Diabetes medicine add-on. In two siblings, ertugliflozin was followed by lower HbA1c.
- Early then later shift. Insulin resistance improved early, then increased later.
- Reported side effects. The report did not describe ketoacidosis or low blood sugar.
July 2026
- ALMS1 variants. Two case reports described new ALMS1 gene variants.
- Genetic confirmation. Genetic testing confirmed Alstrom syndrome in one patient.
- Incomplete eye testing. Diagnosis remained uncertain without key eye exam details.
June 2026
- Publication trends. Alstrom research papers increased quickly after 2020.
- Multi-gene testing. Studies more often used genetic tests that read many genes.
- Breathing tube removal. One case needed repeated, structured steps to remove a breathing tube.
- Autoimmune-type diabetes. One child showed an autoimmune diabetes pattern, which is uncommon.
May 2026
- Heart timing differs. In Alström syndrome, heart problems were reported as starting in infancy for one person and in adulthood for another.
- Infant heart function improved. In one infant with a weak, enlarged heart, pumping function improved after standard heart-failure medicines.
- Atrial flutter treated. In one 20-year-old with atrial flutter and palpitations, the fast rhythm improved after radiofrequency ablation.
- ALMS1 testing tied symptoms together. Genetic testing found ALMS1 changes and helped connect symptoms that appeared at different times into one diagnosis.
April 2026
- Growth hormone and growth. In one reported child with Alström syndrome and growth hormone deficiency, growth improved over time after growth hormone replacement.
- Blood fat levels in one case. The same single-child report described blood fat levels staying in the normal range long-term after treatment.
- New patient stem-cell line. One study added a new patient-derived stem-cell line for Alström syndrome research.
March 2026
- Early weight-gain signal (mice). In a mouse study, DBI/ACBP levels rose before later weight gain and metabolic changes.
- DBI/ACBP blocking (mice). In the same mouse model, antibodies that neutralized DBI/ACBP prevented the usual weight and metabolism changes.
- Genetic diagnosis in adults. A case report showed that ALMS1 genetic testing can confirm Alström syndrome in adulthood when the overall pattern is recognized.
February 2026
- Rat model: metabolic to heart changes. Rats lacking Alms1 developed obesity and insulin resistance first, and later showed high blood pressure and changes in heart structure and function.
- Leptin rose before weight gain. In the same rat model, leptin levels were high early, before obesity was visible, which may help researchers study earlier steps in the metabolic sequence.
- Lab heart-cell formation. In a human stem-cell model, the ALMS1 c.10004G>C variant reduced how efficiently cells became heart muscle cells, while the cells that did form had similar basic beating and muscle structure in the reported tests.
January 2026
- Dulaglutide tracking in one child. In one child with Alström syndrome, dulaglutide use was followed by a lower BMI percentile and a lower HbA1c over time, showing what long-term tracking can capture in a single case.
- Metabolism antibody study in mice. In an Alström-related mouse model, blocking an ACBP-related signal was linked to less weight gain and metabolic measures shifting toward normal, but this is early animal research rather than a human result.
- Clinical diagnosis without genetic testing. One adult case report described a clinical diagnosis made without genetic testing, with short follow-up showing improved blood sugar while vision and hearing did not change.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Alström syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).